IgGErsatztherapie

IgGErsatztherapie, also known as immunoglobulin replacement therapy or IVIg therapy, is a medical treatment used to manage primary immunodeficiency disorders. These are rare genetic conditions where the body's immune system does not produce enough antibodies to fight off infections. In IgGErsatztherapie, healthy antibodies derived from the plasma of human donors are infused into the patient. These donor antibodies, specifically IgG immunoglobulins, supplement the patient's own insufficient antibody levels.

The primary goal of IgGErsatztherapie is to protect individuals with immunodeficiencies from recurrent and potentially life-threatening infections. By providing a consistent supply of antibodies, the therapy helps the patient's immune system neutralize pathogens. The treatment can be administered intravenously, where the immunoglobulins are given directly into a vein, or subcutaneously, where they are injected under the skin. The frequency and dosage of the infusions depend on the individual patient's condition and specific needs.

IgGErsatztherapie is a cornerstone treatment for many primary immunodeficiency diseases, significantly improving quality of life and reducing morbidity and mortality associated with these conditions. It requires ongoing administration, often for a lifetime, and is typically managed by specialized immunology centers. While generally safe, potential side effects can occur, and patients are closely monitored by healthcare professionals.